Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 892.20M P/E - EPS this Y 7.00% Ern Qtrly Grth -
Income -171.53M Forward P/E - EPS next Y 43.70% 50D Avg Chg -4.00%
Sales 50.83M PEG - EPS past 5Y - 200D Avg Chg -18.00%
Dividend N/A Price/Book 78.95 EPS next 5Y - 52W High Chg -64.00%
Recommedations 2.00 Quick Ratio 0.18 Shares Outstanding 131.72M 52W Low Chg 109.00%
Insider Own 32.74% ROA -53.64% Shares Float 56.78M Beta 1.19
Inst Own 21.08% ROE - Shares Shorted/Prior 9.32M/8.23M Price 6.00
Gross Margin 68.24% Profit Margin -233.88% Avg. Volume 525,154 Target Price 5.50
Oper. Margin -95.44% Earnings Date - Volume 695,494 Change 14.94%
About Scilex Holding Company

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California.

Scilex Holding Company News
11/15/24 Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024
11/11/24 Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
11/06/24 Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
10/30/24 Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock
10/30/24 Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms
10/29/24 Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
10/28/24 Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
10/16/24 Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential
10/16/24 Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion
10/10/24 SCLX Grows Sales and Improves Finances
10/08/24 Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024
10/08/24 Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing
10/07/24 Scilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes
10/07/24 Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile
09/26/24 Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025
09/18/24 Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan
09/12/24 Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)
09/12/24 Private companies account for 46% of Scilex Holding Company's (NASDAQ:SCLX) ownership, while institutions account for 22%
09/09/24 Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference
09/05/24 Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024
SCLX Chatroom

User Image JustAGoodOleBoy22 Posted - 1 hour ago

$SCLX $SRNE Not so bad of a month...took a gut shot here w sclx but not as bad as the gut shot the woke took by losing election lmao...they are miserable ...literally falling apart CNN Msnbc ..the he/shes here in ST going bonkers lmao ....love it!!!! FU rainbow rook

User Image Eischcream Posted - 2 hours ago

$SCLX that chart isnt even congruent anymore.... its absokute nonsense

User Image mf3rs Posted - 4 hours ago

$SCLX $srne they probably setting it up to do a "strategic bk". Same cast of characters. Somebody will buy semdexa for pennies and flip it for multi millions.

User Image Tally63 Posted - 4 hours ago

$SCLX

User Image Sacsofcash Posted - 5 hours ago

$SCLX we next?

User Image sububolo Posted - 5 hours ago

$SCLX can you believe that some people would rather keep throwing money into this trash fire instead of investing in $SPY?

User Image sububolo Posted - 5 hours ago

@Vespoucho in all seriousness, yes you have lost everything you invested in $SRNE. if there is any payoff from the $SCLX dividend or the remaining claim, it will be on the order of a few pennies per share at most. if you have $SCLX shares (outside of the dividend), well, you still have 56c of value per share. if you sell now, you won't feel as bad when it falls to 25c, then $10 (after the 100:1 reverse split of course). don't come crying to the board about something something naked shorts when that happens, their financials are public for all the world to see.

User Image Rookie69 Posted - 5 hours ago

$SCLX valid point …….except the fda already said their phase3 wasnt enough re: Semdexa keep pumping and losing

User Image Sacsofcash Posted - 5 hours ago

$SCLX Can a drug still receive NDA approval even if an open-label study isn't completed?👇

User Image Mkav23 Posted - 5 hours ago

$SCLX Schwab is keep sending me notification to give my div shares to charity. That’s weird. Now the deadline is Dec 13th.

User Image mf3rs Posted - 6 hours ago

$SCLX $srne no comment necessary

User Image Rookie69 Posted - 6 hours ago

$SCLX whomever is ”environmental law” on BoB is the biggest idiot on that board and thats saying something

User Image Jigoingtoprison Posted - 6 hours ago

$SCLX my opinion the $2 offer this company is holding back on earnings knowing the price will fall. Trying to make the $2 seem like a great deal. After dec 13 they will release the earnings. This is a bs way to F the share holders again in my eyes.sclx hated this move… if they don’t figure something out with the stock price dilution will have to happen. Fire JI and watch the stock rise. I won’t buy more until he’s gone. How he’s still apart of anything is beyond me.

User Image arghhhh Posted - 7 hours ago

$SCLX right! Because being optimistic has been the way to go!!!!

User Image donotask Posted - 8 hours ago

$SCLX Bears give up 💯‼️

User Image Sacsofcash Posted - 8 hours ago

$SCLX 💥 Here we go! https://search.app?link=https%3A%2F%2Fwww.barrons.com%2Farticles%2Fsec-chair-gensler-resign-inaguration-day-7eb9b95a&utm_campaign=aga&utm_source=agsadl1%2Csh%2Fx%2Fgs%2Fm2%2F4

User Image Bat_shtt_crazy Posted - 9 hours ago

$SCLX Listen to Dean. Been shorting 50 years covered at .60 and went long. I’m buying like hell down here. Let’s make some money. It’s our time now

User Image Stockweiller32 Posted - 10 hours ago

$SCLX $SRNE I’m not trying to be a dick here got real good friends with losses , however a word of caution ⚠️ is that henriod knows this chat place exists, there was a time with 70k followers we all spammed at motley fool event & made him feel like a rock star , the motley fool guys quote was ( I better ask you this question or your followers will burn my house down ) I don’t remember the question , he could have a account here or his cousin in Singapore 🇸🇬, so one of these guys 👇yea … not financial advice!

User Image Rookie69 Posted - 10 hours ago

$SCLX It most certainly makes sense to correlate the ultra rare disease space to generic steroids Keep dreaming and racking up the losses you're doing great

User Image Sacsofcash Posted - 10 hours ago

$SCLX https://search.app?link=https%3A%2F%2Fwww.biospace.com%2F6-drugs-approved-despite-failed-trials-or-minimal-data&utm_campaign=aga&utm_source=agsadl1%2Csh%2Fx%2Fgs%2Fm2%2F4

User Image DeanWitter33 Posted - 11 hours ago

$SCLX explosive move enroute shorts will be braised

User Image JustAGoodOleBoy22 Posted - 11 hours ago

$SCLX $SRNE Hint for Sharm and Rainbow rook https://www.newsweek.com/donald-trump-ellen-degeneres-portia-de-rossi-moved-uk-election-1989325

User Image TopAdvance Posted - 11 hours ago

$SCLX $SRNE This guy is very nervous. I get it brother. If I were you, I’d be terrified.

User Image bestgrass Posted - 11 hours ago

$SCLX Bankruptcy Friday?

User Image Awaywithshorts Posted - 11 hours ago

$SCLX 🤡

User Image DeanWitter33 Posted - 12 hours ago

$SCLX Quiet before the storm

User Image Sharmuda Posted - 12 hours ago

$SCLX Pseudoprofound Bullshit Receptivity and Its Implications While Dr. Frankfurt sparked the academic study of bullshit and bullshitting, few have advanced our knowledge of “bullshittees”—those who consume bullshit—more than Regina University psychology professor Dr. Gordon Pennycook. He and his colleagues won an 👉Ig Nobel Prize 👈for developing a questionnaire designed to quantify receptiveness to a particular kind of bullshit that they called “pseudoprofound bullshit." The Bullshit Receptivity Scale (BRS) asks respondents to rate the profoundness of “seemingly impressive assertions that are presented as true and meaningful but are actually vacuous” Across various research studies, bullshit receptivity has been associated with paranormal and pseudoscientific beliefs, belief in conspiracy theories, the tendency to perceive connections between unrelated things, and the tendency to perceive false or fake news as accurate as well as a willingness to share it on social media.

User Image donotask Posted - 13 hours ago

$SCLX ‼️

User Image DeanWitter33 Posted - 13 hours ago

$SCLX where are all the sellers today 🤔

User Image lealbinagor98 Posted - 13 hours ago

$SCLX earnings just around the corner, it is not advisable to be pessimistic, great action for an incredible rise that is coming

Analyst Ratings
HC Wainwright & Co. Buy Jun 17, 24
Rodman & Renshaw Buy Jun 13, 24
HC Wainwright & Co. Buy Jun 11, 24
HC Wainwright & Co. Buy May 23, 24
HC Wainwright & Co. Buy May 3, 24
HC Wainwright & Co. Buy Dec 4, 23
B. Riley Securities Buy Oct 13, 23
HC Wainwright & Co. Buy Oct 9, 23